Search company, investor...
Okogen company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Alive

Total Raised


Last Raised

$10M | 5 yrs ago

About Okogen

Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.

Okogen Headquarters Location

2009 Woodmoss Ct

Encinitas, California, 92024,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Okogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Okogen is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Okogen Patents

Okogen has filed 3 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Disorders of conjunctiva
  • Inflammations
patents chart

Application Date

Grant Date


Related Topics




Inflammations, G protein coupled receptors, Disorders of conjunctiva, Diseases of the eye and adnexa, Cytokines


Application Date


Grant Date



Related Topics

Inflammations, G protein coupled receptors, Disorders of conjunctiva, Diseases of the eye and adnexa, Cytokines



Latest Okogen News

EYEG Stock Increases Over 135% Pre-Market: Why It Happened

Jul 27, 2021

The stock price of EyeGate Pharmaceuticals Inc (NASDAQ: EYEG) increased by over 135% pre-market. This is why it happened. The stock price of EyeGate Pharmaceuticals Inc (NASDAQ: EYEG) – a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system – increased by over 135% pre-market. Investors are responding positively to EyeGate Pharmaceuticals announcing that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. Plus EyeGate has entered a non-binding letter of intent (LOI) to buy Bayon Therapeutics, a private ophthalmic specialty pharmaceutical company focused on using light-sensitive ‘photoswitch’ small molecules, specifically designed to restore vision in patients with inherited and age-related degenerative retinal diseases. Strem is a biotech executive and entrepreneur with a strong ophthalmology background. Dr. Strem co-founded Bayon Therapeutics where he in-licensed global exclusive rights to the Intellectual Property covering multiple generations of photoswitches. And the lead small molecule, termed “BENAQ”, is being prepared for a Phase 1b clinical trial in patients with late-stage retinitis pigmentosa. Dr. Strem also co-founded Okogen, an ophthalmic company focused on a novel therapeutic for the treatment of viral infections of the eye, where he was most recently, Director and Chief Executive Officer. And Dr. Strem led a successful Series A financing and was responsible for all aspects of corporate strategy, intellectual property, fundraising, drug development, market access and positioning. Before founding Bayon and Okogen, Dr. Strem held leadership positions at Sound Pharmaceuticals as VP of Business Development, as well as Allergan, where he served as Director of Global Business Development and was instrumental in M&A and licensing for ophthalmology and drug development. Before joining Allergan, Dr. Strem was Director of Global Business Development at Shire Pharmaceuticals, where he was responsible for scientific licensing of new therapeutics in regenerative medicine, rare disease, and ophthalmology. Pursuant to the Term Sheet, EyeGate and Bayon intend to negotiate and enter into a definitive agreement pursuant to which EyeGate would buy Bayon in connection for closing consideration of 50,000 shares of the EyeGate’s common stock, and potential earnout consideration of up to approximately $7.1 million or, in EyeGate’s discretion, up to approximately 2.2 million shares of the Eyegate’s common stock or common stock equivalents, based on the achievement of successive milestones based on clinical trial data and regulatory approval of Bayon products. The further terms of the proposed transaction will be provided by upon EyeGate and Bayon entering into a definitive agreement for the transaction. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will happen at all. KEY QUOTES: “Brian’s dynamic entrepreneurship, business development achievements and ability to drive his vision forward makes him exceptionally well qualified for this significant inflection point in EyeGate’s evolution. We are pleased by the recent advancements across our clinical development program for PP-001 and OBG: two unique platforms with broad therapeutic potential among a diverse range of ocular surface and systemic diseases. We look forward to building on this momentum, and we have the greatest confidence in Brian and the executive team’s ability to marshal the necessary resources to maximize the value of our platform, explore additional pipeline expansion opportunities and successfully lead EyeGate through this next phase of continued growth.” “We would like to thank Franz Obermayr, PhD., for his leadership as Acting Chief Executive Officer, and we look forward to continued collaboration as he transitions and reassumes his position as EVP Clinical Development.” — Stephen From, Executive Chairman of EyeGate Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Okogen Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Okogen Rank

  • Where is Okogen's headquarters?

    Okogen's headquarters is located at 2009 Woodmoss Ct, Encinitas.

  • What is Okogen's latest funding round?

    Okogen's latest funding round is Series A.

  • How much did Okogen raise?

    Okogen raised a total of $10M.

  • Who are the investors of Okogen?

    Investors of Okogen include Brandon Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.